Association between positive cancer screening and death from cardiovascular disease
Principal Investigator
Name
yubei huang
Degrees
M.D., Ph.D
Institution
Tianjin Medical University Cancer Institute and Hospital
Position Title
Research Associate
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-1125
Initial CDAS Request Approval
Dec 8, 2022
Title
Association between positive cancer screening and death from cardiovascular disease
Summary
Cardiovascular disease (CVD) and cancer are the two leading causes of death or premature death worldwide. Common risk factors, similar pathogenesis and progression associated with chronic inflammation, and potential interactions between carcinogenic factors and CVD risk factors all predispose cancer and CVD to become a growing global health problem.
In addition, there is growing evidence that cancer patients consistently face an increased risk of death from cardiovascular disease. In addition to the consequences of treatment or the burden of living with progressive cancer, the psychological stress or traumatic experience caused by the cancer diagnosis itself increases the risk of serious adverse health outcomes beyond the effects of the disease or treatment. Similarly, a positive cancer screening test can trigger similar psychological harm, and adverse health consequences. However, few studies have examined the risk of death from CVD following a positive cancer screening test. Unlike a cancer diagnosis, which immediately increases the risk of adverse health outcomes, a positive cancer screening test can haunt patients for a long time, even if there is ultimately no cancer diagnosis. At the same time, participants who test positive by cancer screening may also actively adopt or passively follow the drug in order to reduce or reverse the potential cancer risk.
Therefore, based on the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, we first aimed to explore whether positive cancer screening increased or decreased the risk of CVD death. We then further explore whether the risk of CVD deaths varies by number and type of positive screenings, subgroup-specific risk of CVD mortality based on prior cardiovascular disease and sex, and explore the association of false-positive screenings with CVD mortality after excluding true positive screenings.
In addition, there is growing evidence that cancer patients consistently face an increased risk of death from cardiovascular disease. In addition to the consequences of treatment or the burden of living with progressive cancer, the psychological stress or traumatic experience caused by the cancer diagnosis itself increases the risk of serious adverse health outcomes beyond the effects of the disease or treatment. Similarly, a positive cancer screening test can trigger similar psychological harm, and adverse health consequences. However, few studies have examined the risk of death from CVD following a positive cancer screening test. Unlike a cancer diagnosis, which immediately increases the risk of adverse health outcomes, a positive cancer screening test can haunt patients for a long time, even if there is ultimately no cancer diagnosis. At the same time, participants who test positive by cancer screening may also actively adopt or passively follow the drug in order to reduce or reverse the potential cancer risk.
Therefore, based on the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, we first aimed to explore whether positive cancer screening increased or decreased the risk of CVD death. We then further explore whether the risk of CVD deaths varies by number and type of positive screenings, subgroup-specific risk of CVD mortality based on prior cardiovascular disease and sex, and explore the association of false-positive screenings with CVD mortality after excluding true positive screenings.
Aims
(1) Exploring the relationship between positive cancer screening and the risk of CVD deaths
(2) To explore the specific risk of different subgroups
(3) To explore the relationship between false-positive screening and CVD mortality
Collaborators
Yubei, Huang, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China